Overactive bladder: strategies to ensure treatment compliance and adherence

References

• HaylenBTde RidderDFreemanRMAn International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunctionNeurourol Urodyn201029142019941278
   PubMed Web of Science ®Google Scholar
• AbramsPCardozoLFallMThe standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence SocietyUrology2003611374912559262
   PubMed Web of Science ®Google Scholar
• IrwinDEMilsomIHunskaarSPopulation-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC studyEur Urol200650613061314 discussion 1314–130517049716
   PubMed Web of Science ®Google Scholar
• CanadaSPopulation Projections for Canada, Provinces and Territories: 2009 to 2036OttawaStatistics Canada2010
   Google Scholar
• OfNSPopulation Ageing in the United Kingdom, its Constituent Countries and the European UnionLondonONS2012
   Google Scholar
• IrwinDEMilsomIReillyKOveractive bladder is associated with erectile dysfunction and reduced sexual quality of life in menJ Sex Med20085122904291019090944
   PubMed Web of Science ®Google Scholar
• WagnerTHHuTWBentkoverJHealth-related consequences of overactive bladderAm J Manag Care2002819 SupplS598S60712516954
   PubMed Web of Science ®Google Scholar
• ThomDHHaanMNVan Den EedenSKMedically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortalityAge Ageing19972653673749351481
   PubMed Web of Science ®Google Scholar
• KirbyMGWaggACardozoLOveractive bladder: Is there a link to the metabolic syndrome in men?Neurourol Urodyn20102981360136420589717
   PubMed Web of Science ®Google Scholar
• LucasMGBoschRJBurkhardFCEuropean Association of Urology guidelines on assessment and nonsurgical management of urinary incontinenceActas Urol Esp201337419921323452548
   PubMed Web of Science ®Google Scholar
• Urinary Incontinence in Women: The Management of Urinary Incontinence in WomenLondonNational Institute for Clinical Excellence2013
   Google Scholar
• JonesCHillJChappleCGuideline Development GroupManagement of lower urinary tract symptoms in men: summary of NICE guidanceBMJ2010340c235420484350
   PubMed Web of Science ®Google Scholar
• WaggAVerdejoCMolanderUReview of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladderInt J Clin Pract20106491279128620529135
   PubMed Web of Science ®Google Scholar
• ChappleCRKhullarVGabrielZMustonDBitounCEWeinsteinDThe effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysisEur Urol200854354356218599186
   PubMed Web of Science ®Google Scholar
• ChappleCRCardozoLNittiVWSiddiquiEMichelMCMirabegron in overactive bladder: A review of efficacy, safety, and tolerabilityNeurourol Urodyn2014331173024127366
   PubMed Web of Science ®Google Scholar
• AbramsPAnderssonKEBirderLFourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinenceNeurourol Urodyn201029121324020025020
   PubMed Web of Science ®Google Scholar
• AbramsPLarssonGChappleCWeinAJFactors involved in the success of antimuscarinic treatmentBJU Int1999832 Suppl424710210604
   PubMed Web of Science ®Google Scholar
• CramerJARoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health2008111444718237359
   PubMed Web of Science ®Google Scholar
• HaynesRBMcKibbonKAKananiRSystematic review of randomised trials of interventions to assist patients to follow prescriptions for medicationsLancet199634890243833868709739
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med20055348749716079372
   PubMed Web of Science ®Google Scholar
• AbramsPKelleherCJKerrLARogersRGOveractive bladder significantly affects quality of lifeAm J Manag Care2000611 SupplS580S59011183901
   PubMed Web of Science ®Google Scholar
• AndradeSEWalkerAMGottliebLKDiscontinuation of antihyperlipidemic drugs – do rates reported in clinical trials reflect rates in primary care settings?N Engl J Med199533217112511317700285
   PubMed Web of Science ®Google Scholar
• MonaneMBohnRLGurwitzJHGlynnRJAvornJNoncompliance with congestive heart failure therapy in the elderlyArch Intern Med199415444334378117176
   PubMedGoogle Scholar
• PartridgeAHWangPSWinerEPAvornJNonadherence to adjuvant tamoxifen therapy in women with primary breast cancerJ Clin Oncol200321460260612586795
   PubMed Web of Science ®Google Scholar
• YuYFNicholMBYuAPAhnJPersistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid programValue Health20058449550516091027
   PubMed Web of Science ®Google Scholar
• SextonCCNotteSMMaroulisCPersistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literatureInt J Clin Pract201165556758521489081
   PubMed Web of Science ®Google Scholar
• GomesTJuurlinkDNMamdaniMMComparative adherence to oxybutynin or tolterodine among older patientsEur J Clin Pharmacol2012681979921710237
   PubMed Web of Science ®Google Scholar
• WaggACompionGFaheyASiddiquiEPersistence with prescribed antimuscarinic therapy for overactive bladder: a UK experienceBJU Int2012110111767177422409769
   PubMed Web of Science ®Google Scholar
• WaggADilesDFour year persistence and drug treatment patterns in overactive bladder: data from Canadian datasetsPaper presented at: 68th Annual Meeting of the Canadian Urological Association2013Niagara Falls, ON
   Google Scholar
• WaggADilesDBernerTTreatment patterns for patients on overactive bladder therapy: A retrospective statistical analysis using Canadian claims dataJHEOR201534345
   Google Scholar
• ShayaFTBlumeSGuAZyczynskiTJumadilovaZPersistence with overactive bladder pharmacotherapy in a Medicaid populationAm J Manag Care2005114 SupplS121S12916161385
   PubMed Web of Science ®Google Scholar
• WaggAFranksBRamosBBernerTPersistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in CanadaCan Urol Assoc J201599–1034335026644809
   PubMed Web of Science ®Google Scholar
• D’SouzaAOSmithMJMillerLADoyleJArielyRPersistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care planJ Manag Care Pharm200814329130118439051
   PubMed Web of Science ®Google Scholar
• BennerJSBeckerRFanningKJumadilovaZBavendamTBrubakerLOAB Medication Use Study Steering CommitteeBother related to bladder control and health care seeking behavior in adults in the United StatesJ Urol200918162591259819375096
   PubMed Web of Science ®Google Scholar
• KruegerKPBergerBAFelkeyBMedication adherence and persistence: a comprehensive reviewAdv Ther200522431335616418141
   PubMed Web of Science ®Google Scholar
• SchabertVFBavendamTGoldbergELTrocioJNBrubakerLChallenges for managing overactive bladder and guidance for patient supportAm J Manag Care2009154 SupplS118S12219355801
   PubMedGoogle Scholar
• BennerJSNicholMBRovnerESPatient-reported reasons for discontinuing overactive bladder medicationBJU Int201010591276128219912188
   PubMed Web of Science ®Google Scholar
• HjalmasKHellstromAMogrenKLäckgrenGStenbergAThe overactive bladder in children: a potential future indication for tolterodineBJU Int20018756957411298060
   PubMed Web of Science ®Google Scholar
• RolnickSJPawloskiPAHedblomBDAscheSEBruzekRJPatient characteristics associated with medication adherenceClin Med Res2013112546523580788
   PubMedGoogle Scholar
• Al-HajjeAAwadaSRachidiSFactors affecting medication adherence in Lebanese patients with chronic diseasesPharm Pract201533590
   Google Scholar
• GoldDTMcClungBApproaches to patient education: emphasizing the long-term value of compliance and persistenceAm J Med20061194 Suppl 1S32S3716563940
   PubMed Web of Science ®Google Scholar
• BalkrishnanRBhosleMJCamachoFTAndersonRTPredictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort studyJ Urol20061753 Pt 110671071 discussion 1071–107216469620
   PubMed Web of Science ®Google Scholar
• LaufsURettig-EwenVBöhmMStrategies to improve medication adherenceEur Heart J201132326426820729544
   PubMed Web of Science ®Google Scholar
• MooreTNeherJOSafranekSFPIN’s clinical inquiries: improving medication adherence in patients with comorbiditiesAm Fam Physician20118471222117269
   PubMedGoogle Scholar
• HaynesRBAcklooESahotaNMcDonaldHPYaoXInterventions for enhancing medication adherenceCochrane Database Syst Rev20082CD00001118425859
   PubMed Web of Science ®Google Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther20012381296131011558866
   PubMed Web of Science ®Google Scholar
• ColemanCILimoneBSobierajDMDosing frequency and medication adherence in chronic diseaseJ Manag Care Pharm201218752753922971206
   PubMed Web of Science ®Google Scholar
• BangaloreSKamalakkannanGParkarSMesserliFHFixed-dose combinations improve medication compliance: A meta-analysisAm J Med2007120871371917679131
   PubMed Web of Science ®Google Scholar
• ShrankWHHoangTEttnerSLThe implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditionsArch Intern Med200666333233716476874
   PubMedGoogle Scholar
• BriesacherBAAndradeSEFouayziHChanKAMedication adherence and the use of generic drug therapiesAm J Manag Care200915745045619589012
   PubMed Web of Science ®Google Scholar
• ConnVSRupparTMChanKCDunbar-JacobJPepperGADe GeestSPackaging interventions to increase medication adherence: systematic review and meta-analysisCurr Med Res Opin201531114516025333709
   PubMed Web of Science ®Google Scholar
• TrocioJNBrubakerLSchabertVFFesoterodine prescription fill patterns and evaluation of the YourWay patient support plan for patients with overactive bladder symptoms and physiciansPostgrad Med2014126324625624918809
   PubMed Web of Science ®Google Scholar
• KlutkeCGBurgioKLWymanJFCombined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medicationJ Urol200918162599260719375110
   PubMed Web of Science ®Google Scholar
• SungHHHanDHKimTHInterventions do not enhance medication persistence and compliance in patients with overactive bladder: a 24 weeks, randomised, open-label, multi-center trialInt J Clin Pract201569111309131526215431
   PubMed Web of Science ®Google Scholar
• WymanJFBurgioKLNewmanDKPractical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinenceInt J Clin Pract20096381177119119575724
   PubMed Web of Science ®Google Scholar
• VaradharajanSJumadilovaZGirasePOllendorfDAEconomic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladderAm J Manag Care2005114 SupplS140S14916161387
   PubMed Web of Science ®Google Scholar
• StaskinDRTeAEShort- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinenceBJU Int20069761256126116686722
   PubMed Web of Science ®Google Scholar